Versartis Company Profile (NASDAQ:VSAR)

About Versartis

Versartis logoVersartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company's product pipeline includes VRS-317 and XTEN Technology. The Company's VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company's XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VSAR
  • CUSIP:
Key Metrics:
  • Previous Close: $15.70
  • 50 Day Moving Average: $14.95
  • 200 Day Moving Average: $13.18
  • 52-Week Range: $6.17 - $16.55
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.06
  • P/E Growth: 0.00
  • Market Cap: $568.90M
  • Outstanding Shares: 34,795,000
  • Beta: 2.35
Profitability:
  • Return on Equity: -64.93%
  • Return on Assets: -56.92%
Debt:
  • Current Ratio: 3.02%
  • Quick Ratio: 3.02%
Additional Links:
Companies Related to Versartis:

Analyst Ratings

Consensus Ratings for Versartis (NASDAQ:VSAR) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $23.60 (44.34% upside)

Analysts' Ratings History for Versartis (NASDAQ:VSAR)
Show:
DateFirmActionRatingPrice TargetDetails
1/21/2017Piper Jaffray CompaniesSet Price TargetBuy$22.00View Rating Details
12/20/2016Credit Suisse GroupUpgradeNeutral -> Outperform$11.00 -> $20.00View Rating Details
12/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$25.00View Rating Details
11/9/2016Canaccord GenuitySet Price TargetBuy$28.00View Rating Details
8/11/2016Citigroup Inc.Set Price TargetBuy$17.00 -> $23.00View Rating Details
4/30/2016Morgan StanleyReiterated RatingHoldView Rating Details
4/7/2016Northland SecuritiesInitiated CoverageOutperformView Rating Details
2/2/2016Cowen and CompanyReiterated RatingBuyView Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Versartis (NASDAQ:VSAR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/17/2017        
7/28/2016Q2($0.78)($0.75)ViewN/AView Earnings Details
2/18/2016Q415($0.71)($0.69)ViewN/AView Earnings Details
10/29/2015Q3($0.79)($0.69)ViewN/AView Earnings Details
8/4/2015Q2($0.64)($0.67)ViewN/AView Earnings Details
5/6/2015($0.70)($0.79)ViewN/AView Earnings Details
2/12/2015Q414($0.53)($0.65)ViewN/AView Earnings Details
11/6/2014Q3 14($0.46)($0.57)ViewN/AView Earnings Details
5/5/2014Q114($6.37)($2.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Versartis (NASDAQ:VSAR)
Current Year EPS Consensus Estimate: $-3.08 EPS
Next Year EPS Consensus Estimate: $-2.70 EPS

Dividends

Dividend History for Versartis (NASDAQ:VSAR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Versartis (NASDAQ:VSAR)
Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 70.15%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/13/2017Perceptive Advisors LlcMajor ShareholderBuy94,016$15.30$1,438,444.80View SEC Filing  
2/9/2017Perceptive Advisors LlcMajor ShareholderBuy145,823$13.72$2,000,691.56View SEC Filing  
2/3/2017Jay ShepardInsiderSell6,719$13.69$91,983.11View SEC Filing  
2/2/2017Jay ShepardInsiderSell24,211$13.77$333,385.47View SEC Filing  
1/30/2017Jay ShepardInsiderSell17,270$13.52$233,490.40View SEC Filing  
1/30/2017Joshua T BrummCFOSell2,945$13.85$40,788.25View SEC Filing  
1/30/2017Paul WestbergSVPSell1,916$13.85$26,536.60View SEC Filing  
1/11/2017Paul WestbergVPSell7,931$15.24$120,868.44View SEC Filing  
1/10/2017Paul WestbergVPSell11,213$15.66$175,595.58View SEC Filing  
1/9/2017Paul WestbergVPSell13,356$15.93$212,761.08View SEC Filing  
12/30/2016Perceptive Advisors LlcMajor ShareholderBuy94,750$14.66$1,389,035.00View SEC Filing  
12/29/2016Perceptive Advisors LlcMajor ShareholderBuy47,375$14.37$680,778.75View SEC Filing  
12/27/2016Joshua T BrummCFOSell990$15.85$15,691.50View SEC Filing  
12/27/2016Paul WestbergVPSell361$15.85$5,721.85View SEC Filing  
12/16/2016Paul WestbergVPSell5,000$15.00$75,000.00View SEC Filing  
12/8/2016Edmon R JenningsDirectorSell1,500$12.96$19,440.00View SEC Filing  
12/7/2016Joshua T BrummCFOSell3,021$13.25$40,028.25View SEC Filing  
10/3/2016Srinivas AkkarajuDirectorBuy571,429$12.25$7,000,005.25View SEC Filing  
8/25/2016John VarianDirectorSell1,600$12.97$20,752.00View SEC Filing  
8/22/2016Jay ShepardCEOSell5,442$12.88$70,092.96View SEC Filing  
6/15/2016Joshua T BrummCFOSell1,448$10.63$15,392.24View SEC Filing  
6/15/2016Paul WestbergVPSell725$10.63$7,706.75View SEC Filing  
5/20/2016Joshua T BrummCFOSell1,265$7.87$9,955.55View SEC Filing  
4/21/2016Paul WestbergVPSell1,430$9.68$13,842.40View SEC Filing  
12/30/2015Joshua T BrummCFOSell990$12.44$12,315.60View SEC Filing  
12/30/2015Paul WestbergVPSell362$12.44$4,503.28View SEC Filing  
11/12/2015Joshua T BrummCFOBuy2,500$9.99$24,975.00View SEC Filing  
11/11/2015R Scott GreerDirectorBuy10,000$10.17$101,700.00View SEC Filing  
7/6/2015Paul WestbergVPSell2,400$15.00$36,000.00View SEC Filing  
6/3/2015Paul WestbergVPSell2,400$16.73$40,152.00View SEC Filing  
5/4/2015Paul WestbergVPSell2,400$17.47$41,928.00View SEC Filing  
4/14/2015Jeffrey L ClelandCEOSell8,000$20.13$161,040.00View SEC Filing  
4/6/2015Paul WestbergVPSell2,400$17.49$41,976.00View SEC Filing  
3/23/2015Jeffrey L ClelandCEOSell4,000$20.26$81,040.00View SEC Filing  
3/20/2015Jeffrey L ClelandCEOSell3,179$20.03$63,675.37View SEC Filing  
3/10/2015Jeffrey L ClelandCEOSell4,000$20.23$80,920.00View SEC Filing  
3/2/2015Jeffrey L ClelandCEOSell2,871$20.11$57,735.81View SEC Filing  
2/3/2015Paul WestbergVPSell5,000$17.40$87,000.00View SEC Filing  
1/27/2015Aisling Capital Iii LpMajor ShareholderBuy145,000$17.25$2,501,250.00View SEC Filing  
1/27/2015R Scott GreerDirectorBuy5,500$17.25$94,875.00View SEC Filing  
1/22/2015Shahzad MalikDirectorBuy55,000$17.25$948,750.00View SEC Filing  
1/12/2015Jeffrey L ClelandCEOSell4,000$22.85$91,400.00View SEC Filing  
1/5/2015Jeffrey L ClelandCEOSell4,000$21.94$87,760.00View SEC Filing  
1/5/2015Paul WestbergVPSell5,000$22.48$112,400.00View SEC Filing  
12/29/2014Jeffrey L ClelandCEOSell4,000$22.11$88,440.00View SEC Filing  
12/22/2014Jeffrey L ClelandCEOSell8,000$21.14$169,120.00View SEC Filing  
12/18/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell150,000$19.01$2,851,500.00View SEC Filing  
12/12/2014Paul WestbergVPSell10,000$18.55$185,500.00View SEC Filing  
11/24/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell17,207$18.02$310,070.14View SEC Filing  
11/21/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell26,793$18.04$483,345.72View SEC Filing  
11/20/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell9,000$18.32$164,880.00View SEC Filing  
11/18/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell191,362$19.38$3,708,595.56View SEC Filing  
11/13/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell12,438$19.43$241,670.34View SEC Filing  
11/12/2014Ventures Iv (Jersey) Lp IndexMajor ShareholderSell36,200$19.42$703,004.00View SEC Filing  
9/29/2014Leaf Ventures Ii L.P. NewMajor ShareholderSell12,556$20.02$251,371.12View SEC Filing  
3/27/2014Leaf Ventures Ii L.P. NewDirectorBuy60,000$21.02$1,261,200.00View SEC Filing  
3/26/2014Aisling Capital Iii LpMajor ShareholderBuy60,000$21.00$1,260,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Versartis (NASDAQ:VSAR)
DateHeadline
4-traders.com logoVersartis : Vsar) Vp Sold $175,595.58 in Stock (NASDAQ:VSAR)
www.4-traders.com - February 20 at 7:33 PM
barrons.com logo[$$] Why Biotech Looks Like a Good Bet in 2017 (NASDAQ:VSAR)
www.barrons.com - February 18 at 11:23 AM
thestreet.com logoTwitter Is One of Five Stocks Insiders Really Love Right Now (NASDAQ:VSAR)
www.thestreet.com - February 17 at 6:59 AM
marketexclusive.com logoInsider Trading Activity Versartis, Inc. (NASDAQ:VSAR) – Insider Sold 24,211 shares of Stock (NASDAQ:VSAR)
marketexclusive.com - February 4 at 6:11 AM
4-traders.com logoVERSARTIS, INC. : Change in Directors or Principal Officers (form 8-K) (NASDAQ:VSAR)
www.4-traders.com - February 2 at 6:40 AM
streetinsider.com logoVersartis (VSAR) Names Joshua T. Brumm as COO (NASDAQ:VSAR)
www.streetinsider.com - February 1 at 7:20 AM
finance.yahoo.com logo2:43 am Versartis to present Growth Hormone Deficiency update at Endo; shows consistent safety results over 3 years (NASDAQ:VSAR)
finance.yahoo.com - February 1 at 7:20 AM
finance.yahoo.com logoVersartis Promotes Joshua T. Brumm to Chief Operating Officer and Paul Westberg to Chief Business Officer (NASDAQ:VSAR)
finance.yahoo.com - February 1 at 7:20 AM
4-traders.com logoVersartis' : Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 (NASDAQ:VSAR)
www.4-traders.com - January 31 at 2:16 AM
finance.yahoo.com logoVersartis’ Long-Acting Somavaratan for Growth Hormone Deficiency to be Featured in Multiple Oral and Poster Presentations at ENDO 2017 (NASDAQ:VSAR)
finance.yahoo.com - January 30 at 9:14 PM
seekingalpha.com logoHighlighting Biotech's Versartis' Potential (NASDAQ:VSAR)
seekingalpha.com - January 24 at 3:24 PM
News IconVersartis Inc VSAR Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:VSAR)
www.bioportfolio.com - January 17 at 9:50 AM
thestreet.com logoVersartis' Pipeline Holds Big Promise (NASDAQ:VSAR)
realmoney.thestreet.com - January 13 at 3:44 PM
finance.yahoo.com logoVersartis (VSAR) Shares March Higher, Can It Continue? (NASDAQ:VSAR)
finance.yahoo.com - January 6 at 6:30 AM
4-traders.com logoVersartis, Inc. (NASDAQ:VSAR) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:VSAR)
www.4-traders.com - December 30 at 8:34 PM
insidermonkey.com logo150% Surge in Smart Money Ownership of Versartis Inc (VSAR): What Have They Discovered? (NASDAQ:VSAR)
www.insidermonkey.com - December 4 at 7:24 PM
News IconCommit To Buy Versartis At $10, Earn 46.5% Annualized Using Options (NASDAQ:VSAR)
www.stockoptionschannel.com - December 3 at 7:27 PM
us.rd.yahoo.com logoCoverage initiated on Versartis by SunTrust (NASDAQ:VSAR)
us.rd.yahoo.com - December 2 at 8:10 PM
capitalcube.com logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 (NASDAQ:VSAR)
us.rd.yahoo.com - November 29 at 1:07 PM
News IconVersartis, Inc. VSAR Financial and Strategic SWOT Analysis Review Prices from USD $300 (NASDAQ:VSAR)
www.bioportfolio.com - November 20 at 7:48 PM
finance.yahoo.com logoVERSARTIS, INC. Financials (NASDAQ:VSAR)
finance.yahoo.com - November 10 at 8:19 PM
finance.yahoo.com logoVersartis Presents Safety, Efficacy and IGF-I Data for Somavaratan in Pediatric Growth Hormone Deficiency at the 2016 Congress of the GRS & IGF Society (NASDAQ:VSAR)
finance.yahoo.com - November 10 at 11:59 AM
sg.finance.yahoo.com logoVersartis reports 3Q loss (NASDAQ:VSAR)
sg.finance.yahoo.com - November 3 at 8:20 PM
publicnow.com logoVersartis to Present at Two Investor Conferences in November (NASDAQ:VSAR)
www.publicnow.com - October 31 at 8:47 AM
marketwired.com logoPhase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN® Technology (NASDAQ:VSAR)
www.marketwired.com - October 17 at 7:53 PM
4-traders.com logoVersartis : Phase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology (NASDAQ:VSAR)
www.4-traders.com - October 17 at 7:53 PM
streetinsider.com logoVersartis (VSAR) Approves to Commence Somavaratan Phase 3 in Japan (NASDAQ:VSAR)
www.streetinsider.com - October 17 at 7:53 PM
finance.yahoo.com logoPhase 3 Enrollment Initiated in Japan for Versartis' Long-Acting Growth Hormone Based on Amunix's XTEN(R) Technology (NASDAQ:VSAR)
finance.yahoo.com - October 17 at 7:53 PM
biz.yahoo.com logoVERSARTIS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VSAR)
biz.yahoo.com - October 14 at 7:51 PM
News IconVersartis Inc. (VSAR): Perceptive Advisors Raises Stake (NASDAQ:VSAR)
feedproxy.google.com - October 6 at 1:51 PM
finance.yahoo.com logoCoverage initiated on Versartis by Piper Jaffray (NASDAQ:VSAR)
finance.yahoo.com - October 4 at 7:28 PM
streetinsider.com logoVersartis (VSAR) Prices 4.9M Offering of Common Stock at $12.25/Share (NASDAQ:VSAR)
www.streetinsider.com - September 29 at 7:54 PM
4-traders.com logoVersartis : Announces Pricing of Follow-On Offering (NASDAQ:VSAR)
www.4-traders.com - September 29 at 7:54 PM
publicnow.com logoVersartis Announces Proposed Offering of Common Stock (NASDAQ:VSAR)
www.publicnow.com - September 27 at 7:56 PM
publicnow.com logoVersartis Initiates Phase 3 Trial of Somavaratan in Japan for Children with Growth Hormone Deficiency Following Completion of Phase 2 (NASDAQ:VSAR)
www.publicnow.com - September 26 at 8:13 AM
biz.yahoo.com logoVERSARTIS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:VSAR)
biz.yahoo.com - September 15 at 11:47 AM
capitalcube.com logoVersartis, Inc. :VSAR-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:VSAR)
www.capitalcube.com - September 14 at 12:23 PM
globenewswire.com logoVersartis Presents Data From Up to 30 Months of Somavaratan Treatment for Pediatric Growth Hormone Deficiency at the 2016 ESPE Annual Meeting (NASDAQ:VSAR)
globenewswire.com - September 12 at 7:31 PM
News Icon1} Presents Efficacy, Safety, Metabolic And Adherence Data For Somavaratan In Oral Session At The International Congress Of Endocrinology (NASDAQ:VSAR)
www.biospace.com - September 6 at 8:06 PM
finance.yahoo.com logoVersartis to Present at the Morgan Stanley Global Healthcare Conference (NASDAQ:VSAR)
finance.yahoo.com - September 6 at 8:06 PM
publicnow.com logoVersartis to Host Investor Symposium Featuring Leading Experts in Growth Hormone Deficiency (NASDAQ:VSAR)
www.publicnow.com - September 6 at 8:06 PM
nasdaq.com logoVersartis Presents Efficacy, Safety, Metabolic and Adherence Data for Somavaratan in Oral Session at the International Congress of Endocrinology (NASDAQ:VSAR)
www.nasdaq.com - September 3 at 6:59 PM
streetinsider.com logoVersartis (VSAR) Announces Presentation of Somavaratan Data at 17th ICE in Beijing (NASDAQ:VSAR)
www.streetinsider.com - September 3 at 6:59 PM
nasdaq.com logoLong Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial (NASDAQ:VSAR)
www.nasdaq.com - September 2 at 8:31 AM
4-traders.com logoVersartis : VSAR) Completes Enrollment in Phase III VELOCITY Trial of Somavaratan for the Treatment of Pediatric GHD (NASDAQ:VSAR)
www.4-traders.com - August 27 at 7:13 AM
live-pr.com logoNew Market Report: Versartis, Inc. (VSAR) - Financial and Strategic SWOT Analysis Review (NASDAQ:VSAR)
www.live-pr.com - August 25 at 7:19 AM
streetinsider.com logoVersartis (VSAR) Completes Phase 3 VELOCITY Trial Enrollment (NASDAQ:VSAR)
www.streetinsider.com - August 22 at 8:05 PM
streetinsider.com logoVersartis (VSAR), Teijin Enter Strategic Alliance for Somavaratan in Japan (NASDAQ:VSAR)
www.streetinsider.com - August 10 at 11:26 AM
publicnow.com logoTeijin Limited and Versartis Enter Strategic Alliance for Commercialization of Somavaratan Long-Acting Growth Hormone in Japan (NASDAQ:VSAR)
www.publicnow.com - August 9 at 8:32 PM
finance.yahoo.com logoVersartis to Present at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:VSAR)
finance.yahoo.com - August 4 at 11:28 AM

Social

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

Where is Versartis' stock going? Where will Versartis' stock price be in 2017?

7 brokers have issued twelve-month price objectives for Versartis' shares. Their forecasts range from $20.00 to $28.00. On average, they expect Versartis' stock price to reach $23.60 in the next year.

When will Versartis announce their earnings?

Versartis is scheduled to release their next quarterly earnings announcement on Friday, February, 17th 2017.

What are analysts saying about Versartis stock?

Here are some recent quotes from research analysts about Versartis stock:

  • According to Zacks Investment Research, "Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California. " (1/12/2017)

  • Credit Suisse Group analysts commented, "We are incrementally more optimistic on the VSAR story following last week’s Investor Symposium given the progress the company is making for the well-discussed pediatric indication and also because of what may be an underappreciated opportunity in the adult indication. The stock has had a relatively volatile 12 months (along with much of SMID cap pharma/biotech), but as we start looking ahead to 2017 we see the company as potentially better positioned with the phase 3 data readout in pediatric growth hormone deficiency (GHD) that is expected in 3Q 2017 being the key value driver. The recent Teijen collaboration also puts VSAR in a more secure financial position to see things through on both the pediatric and adult side." (9/19/2016)

Who owns Versartis stock?

Versartis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (11.94%), FMR LLC (11.86%), New Leaf Venture Partners L.L.C. (5.86%), Federated Investors Inc. PA (4.23%), Kingdon Capital Management L.L.C. (1.47%) and State Street Corp (1.28%). Company insiders that own Versartis stock include Edmon R Jennings, Jay Shepard, Jeffrey L Cleland, John Varian, Joshua T Brumm, Paul Westberg, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju.

Who sold Versartis stock? Who is selling Versartis stock?

Versartis' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Dimensional Fund Advisors LP. Company insiders that have sold Versartis stock in the last year include Edmon R Jennings, Jay Shepard, John Varian, Joshua T Brumm and Paul Westberg.

Who bought Versartis stock? Who is buying Versartis stock?

Versartis' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, New Leaf Venture Partners L.L.C., Arrowpoint Asset Management LLC, State Street Corp, FMR LLC, Kingdon Capital Management L.L.C., Renaissance Technologies LLC and A.R.T. Advisors LLC. Company insiders that have bought Versartis stock in the last two years include Joshua T Brumm, Perceptive Advisors Llc, R Scott Greer and Srinivas Akkaraju.

How do I buy Versartis stock?

Shares of Versartis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Versartis stock cost?

One share of Versartis stock can currently be purchased for approximately $16.35.

Versartis (NASDAQ:VSAR) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Earnings History Chart

Earnings by Quarter for Versartis (NASDAQ:VSAR)

Dividend History Chart

Dividend Payments by Quarter for Versartis (NASDAQ:VSAR)

Last Updated on 2/21/2017 by MarketBeat.com Staff